VRTX
Vertex Pharmaceuticals Incorporated
Stock
$504.73−2.01 (−0.40%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.3B | $3.6B | −$493M | $3.5B | $4.1B | $2.6B | $3.3B | $1.6B | $1.3B | $845M | $236M | −$365M | −$573M | −$61M | $268M | $144M | −$635M | −$428M | −$226M |
| Capital expenditures | $497M | $438M | $298M | $200M | $205M | $235M | $260M | $75M | $95M | $99M | $57M | $45M | $51M | $51M | $71M | $35M | $38M | $23M | $32M |
| Free cash flow | $3.8B | $3.2B | −$790M | $3.3B | $3.9B | $2.4B | $3.0B | $1.5B | $1.2B | $746M | $180M | −$411M | −$624M | −$112M | $197M | $109M | −$673M | −$451M | −$259M |
| Stock-based compensation | $689M | $686M | $699M | $581M | $491M | $441M | $430M | $361M | $325M | $293M | $241M | $231M | $178M | $127M | $114M | $118M | $91M | $87M | $58M |
| Buybacks | $2.0B | $2.0B | $1.2B | $428M | $0 | $1.4B | $539M | $186M | $350M | $0 | $0 | — | — | — | — | — | — | — | — |
| Free cash flow margin | 30.2% | 26.6% | −7.2% | 33.8% | 44.0% | 31.8% | 48.2% | 35.9% | 38.5% | 30.0% | 10.5% | −39.8% | −107.6% | −9.2% | 12.9% | 7.7% | −469.8% | −442.7% | −147.4% |